文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

高出血风险冠心病患者植入BuMA Supreme支架与XIENCE支架后第一、第二个月早期新生内膜情况的前瞻性多中心随机OCT研究:随机对照试验研究方案

A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-06-07

主要终点为第一、第二个月支架 strut 新生内膜覆盖率,旨在证明BuMA Supreme支架在早期新生内膜形成方面不劣于XIENCE支架。

要点

  • 高出血风险冠心病患者中,BuMA Supreme支架与XIENCE支架早期新生内膜形成对比的多中心随机OCT研究方案。
  • 主要终点为第一、第二个月支架 strut 新生内膜覆盖率,设计为非劣效性检验。
  • 结果将提供PCI术后1-2个月两种支架新生内膜形成的首个精确影像学证据。

核心结论

  • 本试验旨在证明BuMA Supreme支架在早期新生内膜形成方面不劣于XIENCE支架。
  • 结果将提供BuMA Supreme支架与Xience支架在PCI术后1-2个月新生内膜形成的首个精确影像学证据,并应启发对双联抗血小板治疗(DAPT)的进一步探索与调整。

研究设计与样本

  • 前瞻性、多中心、随机试验。
  • 每个队列内患者再按1:1随机分为植入BuMA Supreme支架组或Xience V/Prime/Xpedition支架组。
  • 主要终点为第一、第二个月支架 strut 新生内膜覆盖率(%)。

关键数值与推荐

  • 主要终点:第一、第二个月支架 strut 新生内膜覆盖率(%)。
  • 次要终点包括新生内膜增生面积/体积、新生内膜增生厚度、支架 strut 贴壁不良率、晚期管腔丢失(LLL)、再狭窄率、器械/病变/临床成功率、第一及第二个月器械导向复合终点、随访期支架血栓及其他严重不良事件和出血事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Earlier vascular healing after drug-eluting stent (DES) implantation may reduce the incidence of late stent thrombosis and provide theoretical evidence to shorten dual antiplatelet therapy duration in patients with high bleeding risks. The BuMA supreme stent is a newly developed DES-coated with the sirolimus by using the international patent electronic grafted eG™ technology. Previous randomized trials showed that BuMA stents had better stent-strut coverage at 3-month follow-ups, which were evaluated by optical coherence tomography (OCT). However, there have been a limited number of studies that are directly evaluating the extent of neointima formation at the first and second months after stent implantation in high-bleeding-risk patients with coronary artery disease. This clinical trial is designed to demonstrate the non-inferiority of the BuMA supreme stent compared to the XIENCE stent in early neointimal formation. METHODS/DESIGN: This is a prospective, multicenter, randomized trial. Forty patients will be assigned into the first-month OCT group, and another 40 patients into the second-month OCT group. The patients in each cohort will be randomized again into two groups in a 1:1 ratio, either being implanted with the BuMA Supreme stent or the Xience V/Prime/Xpedition stent. The primary endpoint is stent-strut neointimal coverage rate (%) at the first and second months, respectively. Secondary endpoints include neointimal hyperplasia area/volume, neointimal hyperplasia thickness, stent-strut malapposition rate, late lumen loss (LLL), restenosis rate, device/lesion/clinical success rate, device-oriented composite endpoints at the first and second months, stent thrombosis and other serious adverse events and bleeding events at follow-up. DISCUSSION: The results will provide the first accurate imaging evidence on neointimal formation of the BuMA Supreme stent and the Xience stent at 1-2 months post PCI. The result should inspire further exploration and adjustment of DAPT treatments. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02747329 . Registered on 21 April 2016. Last updated 17 May 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li B, Jin QH, Chen YD, et al. A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31174600. doi:10.1186/s13063-019-3361-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。